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Moreover, platelets were located homogenously through-
out the matrix in the A-PRF and A-PRF+ groups, whereas 
platelets in PRF were primarily observed within the lower 
portion.  Discussion  the present results show an increase 
growthfactor release by decreased RCF. However,  further 
studies must be conducted to examine the extent to which 
enhancing the amount and the rate of released growth fac-
tors influence wound healing and biomaterial-based tissue 
regeneration.  Conclusion These outcomes accentuate the 
fact that with a reduction of RCF according to the previ-
ously LSCC (described low speed centrifugation concept), 
growth factor release can be increased in leukocytes and 
platelets within the solid PRF matrices.
Keywords Inflammation · Leukocytes · Platelets · 
Platelet-rich-fibrin · Tissue engineering · Vascularization
Introduction
Various blood concentrates are used to support tissue 
regeneration and wound healing in different fields. One of 
these systems is platelet-rich plasma (PRP), a technique 
that has been developed for clinical practice and tissue 
regeneration therapies [1, 2]. PRP is prepared by multiple 
centrifugation steps using patient blood to which antico-
agulants have been added to achieve a platelet-rich concen-
trate that can be used for different indications [3]. However, 
seeking to minimize contamination risk, eliminate addi-
tional anticoagulants and use the autologous and natural 
regeneration capacity, a new system, platelet-rich fibrin 
(PRF), was introduced as the first blood concentrate system 
without additional anticoagulants [4].
PRF is derived from patient venous blood by means of 
single-step centrifugation without the further addition of 
Abstract Purpose The present study evaluated the plate-
let distribution pattern and growth factor release (VEGF, 
TGF-β1 and EGF) within three PRF (platelet-rich-fibrin) 
matrices (PRF, A-PRF and A-PRF+) that were prepared 
using different relative centrifugation forces (RCF) and 
centrifugation times. Materials and methods immunohis-
tochemistry was conducted to assess the platelet distribu-
tion pattern within three PRF matrices. The growth factor 
release was measured over 10  days using ELISA. Results 
The VEGF protein content showed the highest release on 
day 7; A-PRF+ showed a significantly higher rate than 
A-PRF and PRF. The accumulated release on day 10 was 
significantly higher in A-PRF+ compared with A-PRF and 
PRF. TGF-β1 release in A-PRF and A-PRF+ showed sig-
nificantly higher values on days 7 and 10 compared with 
PRF. EGF release revealed a maximum at 24 h in all groups. 
Toward the end of the study, A-PRF+ demonstrated sig-
nificantly higher EGF release than PRF. The accumulated 
growth factor releases of TGF-β1 and EGF on day 10 were 
significantly higher in A-PRF+ and A-PRF than in PRF. 
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any type of anticoagulants. This system was developed 
to fulfill clinical needs by being time-saving and easy to 
use [4]. PRF-based matrices include various inflamma-
tory cells, such as platelets and leukocytes, in combination 
with various plasma proteins embedded in a fibrin network 
[5]. The components of PRF-based matrices are known to 
play an important role during the process of wound heal-
ing. Platelets are the first cells to occur in the region of an 
injury. In addition to their role within hemostasis, platelets 
have inflammatory potential, including the recruitment of 
further inflammatory cells, such as neutrophils and mac-
rophages, and promote angiogenesis and tissue repair [6, 
7]. In this context, platelets are able to express a series of 
biologically active signaling molecules and growth factors, 
such as platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF) and transforming growth 
factor beta (TGF-β). These growth factors are essential 
for tissue vascularization and new tissue formation [8, 
9]. Moreover, platelets contain granules with cytokines, 
chemokines and other inflammatory mediators that are 
released after platelet aggregation to enhance hemostasis 
and activate and recruit cells to the site of inflammation 
[10, 11]. Leukocytes also contribute to angiogenesis and 
lymphangiogenesis by participating in cell–cell cross talk 
and expressing various signaling molecules [12, 13]. The 
extracellular matrix in the wound bed supports the forma-
tion of blood vessels, and fibrin provides a scaffold for the 
inflammatory cells [14].
The structure and constituents of PRF-based matri-
ces were previously explored by our group. An ex  vivo 
histomorphometrical study showed a dense structure and 
specific localization of the included inflammatory cells 
in the lower part of PRF [5]. In addition, a modification 
of the preparation setting based on the previously LSCC 
(described low-speed centrifugation concept) is a first step 
in the reduction of the applied relative centrifugation force 
(RCF). This step was accompanied by a mild increase of 
centrifugation time, resulting in a so-called advanced PRF 
(A-PRF) [5, 15]. Analysis of the structure and composi-
tion of A-PRF revealed a more porous structure compared 
to PRF [5]. In addition, histomorphometrical analysis 
revealed significantly more neutrophilic granulocytes in the 
group of A-PRF compared with PRF [5].
While developing PRF-based matrices, the focus was 
on clot formation, consistency and functional integrity the 
fibrin clot and the distribution of the included inflammatory 
cells to generate PRF-based matrices with high functional-
ity and adequate handling. In this study, the applied RCF 
and centrifugation times are key elements. Further research 
on PRF-based matrices regarding their structure and com-
position indicates that adjusting the centrifugation time, 
i.e., reducing the spinning time and applying the same RCF 
as in the case of A-PRF, allows the introduction of a new 
PRF-based matrix, Advanced-PRF+ (A-PRF+). A previ-
ous systematic study demonstrated the influence of the RCF 
reduction on the leukocyte and platelet numbers as well as 
their role in growth factor release in fluid PRF-based matri-
ces following the LSCC, which indicates that reducing the 
RCF enhances the cell number and growth factor release 
within PRF-based matrices [15]. Based on the LSCC, we 
examined modifications of the RCF and centrifugation 
times in solid PRF-based matricesand their influence on the 
growth factor release within the previously introduced PRF 
protocols with a solid structure; PRF, A-PRF and A-PRF+. 
Therefore, the goal of the present study was to determine 
growth factor release in solid PRF-based matrices, PRF, 
A-PRF and A-PRF+, at six different time points over a 
period of 10  days. Additionally, immunohistochemical 
analysis was conducted to assess the platelet distribution 
pattern within the various PRF-based matrices.
Materials and methods
PRF preparation
For each protocol, peripheral blood was drawn from four 
healthy volunteers between 25 and 60  years of age (two 
females, two males) without a history of anticoagulant 
usage. Informed consent was obtained from each donor 
who participated in this study. As previously described 
[5], the venous blood was collected in 10-ml sterile glass 
tubes (A-PRF tubes Process for PRF™, Nice, France; Mec-
tron, Cologne, Germany) without external anticoagulants 
and placed immediately in a centrifuge (Duo centrifuge, 
Process for PRF™, Nice, France; Mectron, Cologne, Ger-
many). The centrifuge has a fixed angle rotor with a radius 
of 110  mm and no brake. After centrifugation time, the 
centrifugation process ends automatically, and the centri-
fuge stops in 2–5 s. All preparation steps were performed 
at room temperature according to the established protocols 
as follows:
•	 PRF: 10 ml; 2400 rpm; 12 min; 708 g
•	 A-PRF: 10 ml; 1300 rpm; 14 min; 208 g
•	 A-PRF+: 10 ml; 1300 rpm; 8 min; 208 g
After centrifugation, all clots were carefully removed 
from the tubes and separated from the red blood cell frac-
tion with sterile tweezers and scissors.
PRF cultivation
The total clots of PRF, A-PRF and A-PRF+ were placed 
in separate wells of a 6-well plate (Greiner, Bio-One Inter-
national) and covered with 5  ml Roswell Park Memorial 
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Institute medium (RPMI 1640, Gibco Thermo Fischer 
Scientific) without Fetal Bovine Serum and supplemented 
with L-glutamine and 1% penicillin/streptomycin. The clots 
were incubated in a humidified incubator for up to 10 days 
at 37 °C with 5%  CO2. The supernatants from each well 
were taken after 6, 24, 48, 72 h, 7 and 10 days and stored 
as aliquots at −80 °C. At each time point, all of the clots of 
PRF-based matrices were placed into new wells and cov-
ered with 5 ml fresh medium.
Growth factor measurement
The supernatants that were collected from the various 
PRF-based matrices at different cultivation time points 
were used for the quantification of different growth fac-
tors by enzyme-linked immunosorbent assay (ELISA). All 
collected supernatants were simultaneously centrifuged 
(1500 rpm; 5 min.) using a centrifuge (Thermo fisher sci-
entific,  Heraeus®  Labofuge® 400 R) to exclude possible 
residue that could affect the photometrical measurement. 
Before TGF-β1 and EGF ELISA preparation, the super-
natants were diluted 1:4 with the same cell culture RPMI 
medium used for PRF-matrices cultivation. The protein 
concentrations of human VEGF, TGF-β1 and EGF were 
determined by the Dou Set ELISA kit (Human VEGF 
DY293B, R&D Systems, detection range: 2000–31.3  pg/
ml), HumanDou Set ELISA kit (Human TGF-β1 DY240, 
R&D Systems, detection range: 2000–31.3 pg/ml) and the 
Duo Set DuoSet ELISA kit (human EGF DY236, R&D 
Systems, detection range: 3.91–250  pg/mL) according to 
the manufacturer´s instructions. Measurements were con-
ducted using a microplate reader  (Infinite® M200, Tecan, 
Grödig, Austria) set to 450  nm and subtracted at 570  nm 
from the 450 nm measurements.
Immunohistological analysis
As previously described [5, 16], the PRF clots were col-
lected after 10  days and fixed in  Roti®-Histofix 4%, acid 
free (pH 7), and 4% phosphate-buffered formaldehyde 
solution (Carl-Roth) for 24  h. The PRF-based matrices 
were dehydrated in a series of alcohol and xylene through 
a Tissue Processor (TP1020, Leica Biosystems Nussloch 
GmbH, Germany) and embedded in paraffin blocks. After-
wards, 3 µm thick sections from each sample were cut by 
a rotatory microtome (Leica RM2255, Wetzlar, Germany). 
For immunohistochemistry, the sections were deparaffi-
nized, rehydrated and finally sonicated in citrate buffer 
(pH 6) at 96 °C for 20 min. The sections were stained with 
monoclonal mouse anti-human CD61 marker (1:50, Plate-
let Glycoprotein IIIa/APC, Clone Y2/5, Dako) by means of 
an autostainer (Lab vision Autostainer 360, Thermo Fisher 
Scientific). Histological examination was conducted using 
a light microscope (Nikon Eclipse 80i, Tokyo, Japan). 
Three of the authors KE, SA and SG, were independently 
blinded for the morphological analysis. The micropho-
tographs were prepared with a connected DS-Fi1/Digi-
tal camera (Nikon, Tokyo, Japan) and a Digital sight unit 
DS-L2 (Nikon, Tokyo, Japan).
Statistical evaluation
Data were expressed as the mean ± standard deviation. 
Statistical analysis was conducted using Prism Version 6 
(GraphPad Software Inc., La Jolla, USA). The significance 
of differences among means of data was analyzed using 
two-way analysis of variance (ANOVA) with the Tukey 
multiple comparisons test (α = 0.05) of all pairs. The sig-
nificant differences were regarded as significant if the p val-
ues were less than 0.05 (*p < 0.05) and highly significant 
if the p values were less than 0.005 (**p < 0.005), 0.0005 
(***p < 0.0005) or 0.0001 (****p < 0.0001).
Results
General observation of fibrin clotting within the three 
investigated groups
Macroscopic observation demonstrated the formation 
of three slightly different clots. PRF formed a clot with a 
fibrin/red blood count (RBC) ratio of 1/1.66, and the clot 
length was measured as 3.5 cm. A-PRF showed a clot for-
mation with a fibrin/red blood count (RBC) ratio of 1/2. 
Here the clot length was 3.5  cm. A-PRF+ had a fibrin/
red blood count (RBC) ratio of 1/3 and a length of 2.5 cm 
(Fig. 1). Moreover, while separating the fibrin clot from the 
RBC, it was observed that in the case of PRF and A-PRF, 
the adhesion between the two sections, the fibrin clot and 
RBC, was stronger compared with A-PRF+. Accordingly, 
the A-PRF+ fibrin clot was much easier to separate.
Growth factor release kinetics from the clots
The present study focused on the determination of the 
released growth factor kinetics of the three PRF-based 
matrices, PRF, A-PRF and A-PRF+. The growth factors 
VEGF, EGF and TGF-β1 were quantified for the released 
concentrations at each time point (6, 24, 48, 72 h, 7, and 
10  days). Additionally, the accumulated growth factor 
quantities were calculated.
VEGF release
The general trend of the three evaluated groups at each 
time point was similar. The release of VEGF increased in 
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the very early phase from 6 to 24 h in all groups. At 48 h, 
the growth factor release was comparable to the values at 
24  h in all groups. From 48 to 72  h, a slight decrease in 
the release of VEGF was evidenced in all groups. From 
72  h to day 7, a highly significant increase in all groups 
was observed (p < 0.0005) in an intra-individual com-
parison (data not shown). During the 4 days of cultivation 
between 72  h and day 7, the highest released concentra-
tion of VEGF over the study time was measured. Here, 
A-PRF+ showed the highest concentration when com-
pared with PRF and A-PRF (PRF = 158.5 ± 36.6  pg/ml; 
A-PRF = 153.6 ± 40.1  pg/ml; A-PRF+ = 242.35 ± 67.9  pg/
ml), which was statistically highly significant when com-
pared to PRF and A-PRF (p < 0.0005). By contrast, A-PRF 
showed no statistically significant difference compared to 
PRF. From day 7 to day 10, all groups showed a decrease in 
the release of VEGF. This decrease was intra-individually 
statistically highly significant compared with day 7 (data 
not shown). Furthermore, after 10  days, A-PRF+ showed 
the highest VEGF release (PRF = 83.7 ± 28.81  pg/ml; 
A-PRF = 64.84 ± 15.7 pg/ml; A-PRF+ = 95.5 ± 44.7 pg/ml). 
At this time point, no significant difference could be identi-
fied among the groups (Fig. 2a1).
Concerning the accumulated VEGF concentra-
tion, a general trend was also evidenced by a continuous 
increase in the released VEGF over the study time. In the 
early phase (6–72  h), the release of VEGF increased in 
all groups, whereas the groups’ concentrations were quite 
similar. Moreover, in the late study period (72 h–10 days), 
a similar tendency was observed in all groups. However, 
A-PRF+ released the highest concentration on day 10 when 
compared with PRF and A-PRF (Table 1). This difference 
was highly significant when comparing A-PRF+ to A-PRF 
(***p < 0.0005) and significant comparing A-PRF+ to PRF 
(**p < 0.005) at this time point (Fig. 2 a2).
TGF-β1 release
Various TGF-β1 release patterns were measured in PRF, 
A-PRF and A-PRF+. Within the PRF group, a slight 
increase was observed in the early study time (6–72  h) 
followed by a dramatic decrease in the late study time 
(72 h–10 days). At 72 h, PRF already showed the highest 
concentration over the study period. At this time point, 
PRF was significantly higher only when compared to 
A-PRF (p < 0.0001), whereas no significant difference was 
observed compared to A-PRF+ (Fig. 2b1).
The A-PRF group showed a high release value 
at the first time point (6  h) (PRF = 4.6 ± 1.0  ng/ml; 
A-PRF = 7.0 ± 1.4  ng/ml; A-PRF+ = 5.8 ± 1.4  ng/ml), the 
difference between A-PRF and PRF being statistically sig-
nificant (p < 0.05). However, no statistically significant dif-
ference was detected regarding A-PRF+. This observation 
was followed by irregular behavior until 72 h and a signifi-
cant increase at day 7, when the highest TGF-β1 release of 
A-PRF was observed. At this time point, A-PRF was sig-
nificantly higher than PRF (p < 0.0001), whereas no signifi-
cant difference was revealed for the A-PRF+ group.
A-PRF+ showed a mild decrease of the released TGF-
β1 at the early study time (6–48 h). However, from 72 h to 
day 7, an increase in the released TGF-β1 was observed 
when the highest concentration of TGF-β1 release was 
reached in the case of A-PRF+. At day 7, a statistically 
highly significant difference was observed when compared 
with PRF (p < 0.0001), whereas no significant difference 
was observable compared to A-PRF (PRF = 1.9 ± 1.6  ng/
ml; A-PRF = 8.5 ± 0.6  ng/ml; A-PRF+ = 8.6 ± 0.4  ng/ml). 
From day 7 to day 10, the release of TGF-β1 decreased in 
all groups. However, A-PRF showed significantly higher 
values when compared with PRF (p < 0.0001). Similarly, 
A-PRF+ revealed more growth factor release, which was 
highly significant when compared with PRF (p < 0.0001). 
No statistically significant difference was observed 
when comparing A-PRF and A-PRF+ at this time point 
(Fig. 2b1).
The accumulated concentration of TGF-β1 showed 
an increase in all groups at the early study time (6–72 h). 
However, at the late study time (72 h–10 days), the growth 
factor release differed among the various groups. PRF 
showed a more or less constant concentration of TGF-β1 
after 72h, whereas in the case of A-PRF and A-PRF+, an 
Fig. 1  The PRF-based matrices immediately following centrifuga-
tion
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Fig. 2  Statistical analysis of the growth factor releases by time 
points as the mean ± standard deviation for PRF, A-PRF and 
A-PRF+. a1 VEGF, b1 TGF-β1 release, c1 EGF release, (*p < 0.05), 
(***p < 0.0005), (****p < 0.0001). Total accumulated growth factor 
concentration over 10 days. a2 VEGF, b2 TGF-β1, c2 EGF
Table 1  Accumulated growth factor concentration of PRF, A-PRF and A-PRF+ at day 10 as the mean ± standard deviation. Statistical analysis 
of A-PRF and A-PRF+ compared with PRF (*p < 0.05), (**p < 0.005), (***p < 0.0005), (****p < 0.0001)
Growth factor PRF A-PRF A-PRF+
VEGF (pg/ml) 632.26 ± 90.58 593.15 ± 114.08 773.88 ± 117.66**
TGF β1 (ng/ml) 23.18 ± 1.22 34.081 ± 3.21**** 36.29 ± 5.73****
EGF (pg/ml) 858.62 ± 152.90 1106 ± 57.74* 1147.07 ± 164.47**
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increased TGF-β1 concentration was observed. These dif-
ferences on day 10 were statistically significant when com-
paring A-PRF to PRF (p < 0.0001) and A-PRF+ to PRF 
(p < 0.0001); however, no statistically significant difference 
was detected when comparing A-PRF to A-PRF+ (Table 1) 
(Fig. 2b2).
EGF release
A general trend was observed in all three PRF-based 
matrices. The rate of the released EGF increased quite 
early in the study time (6–24  h) to reach the highest 
value in all groups at 24  h. At this time point, A-PRF+ 
showed the highest value of the released EGF when com-
pared with PRF and A-PRF (PRF = 282.69 ± 109.09  pg/
ml; A-PRF = 373.75 ± 101.25  pg/ml; 
A-PRF+ = 435.17 ± 89.29  pg/ml), the difference being 
statistically highly significant when comparing A-PRF+ 
to PRF (***p < 0.0005); no statistical significance was 
observed when comparing A-PRF to A-PRF+. Subse-
quently, a course change was observed when a strong 
reduction of the released EGF occurred in all examined 
groups until 72 h. After that, on day 7, a slight increase was 
observed in all groups. Here also, A-PRF+ was the highest 
(PRF = 148.28 ± 48.27  pg/ml; A-PRF = 138.70 ± 61.07  pg/
ml; A-PRF+ = 173.50 ± 98.72  pg/ml) although no statisti-
cally significant difference was detectable. At the last eval-
uated time point on day 10, all groups showed a significant 
decrease in the released EGF compared with day 7 (data 
not shown). However, at this time point, no statistically 
significant differences were observed among the groups 
(Fig. 2c1).
The accumulated concentration of the released EGF 
also exhibited a general trend. All groups showed a sim-
ilar curve progression in the form of increased EGF 
release over the study time. A-PRF and A-PRF+ also dis-
played similar values. Early in the study time, a remark-
able increase in released EGF was evidenced in all groups. 
After 72 h, only a minor increase of the released EGF was 
observed toward the end of the study on day 10. At these 
time points (72  h–10  days), A-PRF and A-PRF+ showed 
statistically significantly higher release values when com-
pared with PRF (A-PRF+ compared with PRF p < 0.005; 
A-PRF compared with PRF p < 0.05), whereas no statisti-
cally significant differences were revealed when comparing 
A-PRF to A-PRF+ (Table 1) (Fig. 2c2).
Platelet distribution in the PRF-based matrices
Immunohistochemical staining with CD-61 antibodies 
against platelets was conducted to determine the platelet 
distribution in cross sections of the three PRF-based matri-
ces. The platelet distribution was evaluated with regard to 
the location in the clot. The platelets formed accumulations 
within all three clots. PRF, which was prepared with a high 
RCF, showed a different distribution pattern according to 
the localization. The upper and middle portions of the clot 
showed only a few platelets, whereas the majority of plate-
lets were distributed in the lower portion of PRF (Fig. 3). 
By contrast, A-PRF, which was prepared with a reduced 
RCF, presented a different distribution pattern. Platelets 
were dispersed all over the clot (Fig.  4). A-PRF+ with a 
reduced RCF and a reduced centrifugation time also dis-
played an even platelet distribution pattern in the various 
locations within the clot (Fig. 5).
Discussion
This study presents the potential of PRF-based matrices 
(PRF, A-PRF and A-PRF+) for growth factor release as a 
modest contribution to ongoing discussions regarding the 
preparation of PRF-based matrices as biological scaffolds 
and a natural growth factor release system, which is derived 
from autologous blood. The results revealed continuous 
growth factor release of VEGF, TGF-β1 and EGF over the 
study time. However, statistically significant differences 
among the various preparation protocols, PRF, A-PRF and 
A-PRF+, were demonstrated.
One of the most potent angiogenesis-stimulating growth 
factors is VEGF. A-PRF+ released significantly more 
VEGF than PRF and A-PRF on day 7. Moreover, the 
accumulated release of VEGF on day 10 was significantly 
higher in A-PRF+ than in PRF and A-PRF. However, 
no statistical significance was detected when evaluating 
A-PRF and PRF. These outcomes are quite likely related to 
the specific fibrin structure and cellular distribution pattern 
of A-PRF+. VEGF plays a crucial role in wound healing 
and tissue regeneration to promote vascularization and new 
vessel formation [17]. Additionally, previous studies have 
demonstrated that the sustained release of VEGF promotes 
epithelialization and enhances collagen tissue deposition in 
a skin wound healing model in mice [18]. Thus, the sus-
tained and enhanced VEGF release of A-PRF+ could lead 
to more benefits in regeneration and vascularization and 
thus provide a nutrient supply to support wound healing 
and improve the biomaterial-guided regeneration pattern.
The release of TGF-β1 in A-PRF and A-PRF+ indi-
cated the maximal release values on days 7 and 10, which 
were significantly higher when comparing A-PRF to 
PRF and A-PRF+ to PRF. However, no statistically sig-
nificant difference between the TGF-β1 release of A-PRF 
and A-PRF+ was identified. On day 10, the accumulated 
TGF-β1 concentration was significantly higher in the 
A-PRF and A-PRF+ groups than in the PRF group. By 
contrast, A-PRF and A-PRF+ revealed no statistically 
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significant difference in this case. TGF-β 1 is essential 
for wound healing [19]. Chronic wounds were observed 
to have a decreased expression of TGF-β receptors [20]. 
Thus, PRF matrices with an enhanced release of TGF-
β1, as was the case for A-PRF and A-PRF+, could have a 
major influence on wound healing as a catalyzer of wound 
repair stages. In addition, this growth factor is known to 
stimulate fibroblast migration, enhance collagen synthesis 
and promote angiogenesis [21, 22]. All of the latter char-
acteristics are essential in the biomaterial-based regen-
eration process. Hence, PRF-based matrices as an addi-
tional autologous dose of inflammatory cells and growth 
factor could be promising in the field of guided bone and 
tissue regeneration (GTR and GBR), in which biomateri-
als should provide a scaffold and support the regeneration 
process in the defect area.
Fig. 3  CD-61 immunohistochemical analysis of PRF according to 
the different regions. a1, a2 upper portion; b1, b2 middle portion; c1, 
c2 lower portion (a1, b1, c1 total scan sections; ×100 magnification, 
scale bar 500 µm). a2, b2, c2 show the distribution pattern of plate-
lets (yellow arrows) in higher magnification (f fibrin; b buffy coat; 
×400 magnification; scale bar 20 µm)
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The release of EGF was generally higher in the A-PRF 
and A-PRF+ groups when compared with PRF. Statisti-
cally highly significant differences were detected when 
comparing A-PRF+ with PRF after 24 h, whereas no sig-
nificant difference was observed between A-PRF+ and 
A-PRF. The accumulated EGF release showed significantly 
higher rates in the case of A-PRF and A-PRF+ compared 
with PRF at most time points, particularly on day 10. EGF 
has previously been described as promoting cell growth 
[21], enhancing keratinocyte migration [23], inhibiting 
apoptosis under hypoxic conditions [24], and supporting re-
epithelization and skin healing [25, 26]. Additionally, EGF 
supports the healing process of chronic wounds [27], non-
healing chronic wounds and ulcers, which are, for example, 
observed in diabetic patients known to lack the necessary 
growth factors to maintain the healing process [28, 29]. 
Thus, such patient groups may benefit from the application 
of PRF matrices as an autologous drug delivery system. 
Fig. 4  CD-61 immunohistochemical analysis of A-PRF according to 
the different regions. a1, a2 upper portion; b1, b2 middle portion; c1, 
c2 lower portion (a1, b1, c1 total scan sections; ×100 magnification, 
scale bar 500 µm). a2, b2, c2 Show the distribution pattern of plate-
lets (yellow arrows) in higher magnification (f fibrin; b buffy coat; 
×400 magnification; scale bar 20 µm)
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Moreover, immunohistochemical evaluation indicated an 
equal distribution pattern of platelets in all clot regions 
in the case of A-PRF and A-PRF+, whereas in PRF, the 
majority of the platelets were located in the lower portion 
of the clot. These findings may be related to the LSCC (low 
speed centrifugation concept), indicating that reducing 
the applied RCF increases the number inflammatory cells 
and platelets as well as the growth factor release within 
the PRF-based matrices [15]. Because the centrifugation 
process depends on cell weight and density, a higher RCF 
may be the reason for the sedimentation of the majority 
of the platelets to the lower portion of the clot according 
to their density and size, as observed in PRF. Decreasing 
the RCF allows the platelets to become separated from the 
red blood cell phase and become equally distributed within 
the fibrin network. The effectiveness of PRF clots with 
low platelet counts and uneven platelet distribution may 
have less influence on clinical outcomes than clots with 
Fig. 5  CD-61 immunohistochemical analysis of A-PRF+ according 
to the different regions. a1, a2 upper portion; b1, b2 middle portion; 
c1, c2 lower portion (a1, b1, c1 total scan sections; ×100 magnifi-
cation, scale bar 500 µm). a2, b2, c2 Show the distribution pattern 
of platelets (yellow arrows) in higher magnification (f fibrin; b buffy 
coat; ×400 magnification; scale bar 20 µm)
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evenly distributed and enhanced platelet numbers because 
the applied clot could have uneven biological activity and 
thus a reduced growth factor release, as indicated in the 
present study. However, comparative clinical studies are 
necessary to evaluate the advanced PRF matrices presented 
here to demonstrate the extent to which the improved struc-
ture, even cellular distribution and enhanced growth factor 
release may affect clinical outcomes.
These observations highlight the influence of RCF 
reduction, i.e., from PRF (708  g) to A-PRF and A-PRF+ 
(208 g) on platelet distribution, thereby correlating with the 
previously demonstrated automated cell counting that indi-
cated significantly more platelets in PRF matrices prepared 
with low RCF than with high RCF application [15]. A pre-
vious ex vivo immunohistochemical study demonstrated the 
distribution pattern in PRF and A-PRF, which included, in 
addition to platelets, a wide range of inflammatory cells 
that physiologically exist within the peripheral blood, such 
as leukocytes, including neutrophils and monocytes as well 
as lymphocytes [5]. However, further immunohistochemi-
cal studies are required to determine the distribution pat-
tern of the included leukocytes and their subgroups, par-
ticularly in A-PRF+. These cells, particularly platelets and 
neutrophilic granulocytes, contribute to neoangiogenesis 
and VEGF release [30, 31]. In addition, platelets are the 
primary secretory cells of EGF and TGF-β1 [32]; thus, 
their presence within the PRF-based matrices is a possible 
explanation for the observed growth factor release. These 
cells are essential for wound healing and tissue regenera-
tion [33, 34]. In the present study, release kinetics displayed 
an increased growth factor release over the study time and 
a maximum at day 7 in the case of VEGF and TGF-β1 as 
well as an increased growth factor release at 24  h in the 
case of EGF. Based on the growth factor and release kinet-
ics demonstrated here, one may assume that the growth fac-
tor release pattern within the various PRF-based matrices is 
an active release from living cells within the different PRF 
clots, which most likely experienced apoptosis during the 
study period if 10 days reflects the reduction in growth fac-
tor release at day 10 compared with day 7 in all groups and 
growth factors.
Additionally, leukocytes and platelet interaction via 
cellular cross talk have been described in bone regenera-
tion [9]. In this context, the high regeneration potential of 
advanced PRF-based matrices could be beneficial in vari-
ous clinical applications, such as enhancing the regen-
eration pattern of biomaterials in terms of GTR and GBR. 
Moreover, autologous biologizing biomaterials using PRF-
based matrices may improve the regeneration pattern in 
large-sized, soft and bony defects to catalyze wound heal-
ing and regeneration. Ongoing clinical observations in oral- 
and maxillofacial surgery have demonstrated that various 
bony defects within the jaw or head can be regenerated by 
different clot numbers according to the defect size. Thus, 
molar sockets are treated with 2–3 clots, whereas larger 
bony head defects are treated with up to 6 clots. Based on 
these observations, PRF-based matrices could be a ben-
eficial tool to improve the regeneration of soft and bony 
defects after orthopedic or trauma surgery. The present 
study demonstrates that the application of the LSCC (low 
speed centrifugation concept), by decreasing the RCF from 
PRF toward A-PRF and A-PRF+, results in a significantly 
higher release of VEGF, TGF-β1 and EGF. Notably, the 
accumulated release over 10 days of TGF-β1 and EGF sup-
ports the relation between the reduction of RCF and the 
growth factor release. Hence, A-PRF+ and A-PRF, which 
were prepared with the same RCF, displayed comparable 
results that were significantly higher than PRF, which was 
prepared with more than three times higher RCF. These 
observations emphasize the fact that the application of the 
LSCC is valuable in modifying and optimizing solid PRF-
based matrices. However, the manipulation of the centrifu-
gation time appeared to influence only certain growth fac-
tors, as shown in the case of A-PRF+. The accumulated 
VEGF release on day 10 showed a significantly higher rate 
in the group of A-PRF+ compared with A-PRF and PRF. 
It may be that the application of a low RCF but a longer 
centrifugation time, as demonstrated in the case of A-PRF, 
affected the VEGF release capacity, whereas the applica-
tion of a low RCF and slightly decreased centrifugation 
time, as in A-PRF+, resulted in a significantly higher 
VEGF release. Another plausible explanation may be that 
the specific fibrin clot composition of A-PRF+ allows a 
highly increased VEGF release and thus a higher accumu-
lated VEGF release on day 10. These data accentuate the 
fact that the various growth factor concentrations may be a 
consequence of the various total cell concentrations within 
the PRF-based matrices.
The various release profiles of the evaluated PRF-
based matrices may also be a consequence of the differ-
ent growth factor binding affinities to fibrin. It has been 
demonstrated that growth factors, such as VEGF, have a 
high affinity to bind to fibrinogen and fibrin so that those 
factors are released in a sustained manner [35]. This 
information is reflected in the present results by showing 
significantly enhanced VEGF release on day 7 in the case 
of A-PRF+. By contrast, EGF is released in a high con-
centration level at the very early time point of 24 h. One 
explanation for this observation may be the low binding 
affinity of EGF to fibrin and fibrinogen [36]. Another 
factor may be the structure of the PRF-based matrices. 
A-PRF and A-PRF+ exhibit a more porous structure 
than the densely structured PRF [5]. The physical prop-
erties of the clot and the specific fibrin structure related 
to the manufacturing protocol [5] may also influence the 
binding affinity and the sustained release of the various 
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growth factors. It is possible that a more porous struc-
ture, as shown in A-PRF and A-PRF+, is one reason for 
an enhanced growth factor release [5]. Thus, it remains 
questionable whether the growth factor release is related 
to the specific physical properties of the fibrin network or 
to the included inflammatory cells and platelets, or per-
haps a combination of both. Therefore, further study is 
required to understand this specific complex system.
The release kinetics of growth factors in the PRF-based 
matrices have previously been reported in several studies 
[37, 38]. Direct comparisons of these studies are limited 
because of the various preparation protocols in terms of 
RCF, centrifugation time, blood volume and the techniques 
used to generate the PRF-based matrices. However, one 
in  vitro study analyzed the growth factor release in PRF-
based matrices compared with PRP [39]. Correlations 
were demonstrated in the case of the accumulated TGF-β1 
and EGF, for which both studies presented a significantly 
higher growth factor release in PRF matrices prepared with 
a low RCF application compared with PRF matrices with 
high RCF exposure. This accentuates the fact that reduc-
tion of the RCF enhances the release of these growth fac-
tors. Notably, the later study also showed that PRP released 
higher growth factor concentrations (EGF, VEGF and 
TGF-β1) at the very early time points, whereas PRF-based 
matrices showed a continuous and higher growth factor 
concentration over a period of 10 days [39]. Moreover, this 
group demonstrated further evaluation of the growth fac-
tors in PRF, A-PRF and A-PRF+ [40]. The results of the 
accumulated growth factor release on day 10 are consistent 
with the present findings with regard to A-PRF+ concern-
ing TGF β1 and EGF. Both studies presented a significantly 
higher release of these growth factors within A-PRF+ 
when compared with PRF. By contrast to Kobayashi et al. 
(2016), the present study reveals no significant differ-
ences between A-PRF and A-PRF+ with regard to TGF 
β1 and EGF. Additionally, the present outcomes indicate 
significantly higher accumulated VEGF release on day 10 
in the group of A-PRF+ compared with A-PRF and PRF, 
whereas Kobayashi et al. (2016) showed no statistically sig-
nificant differences between the examined groups on day 
10. At this point, it must be stressed that the two studies 
were of different designs. Kobayashi et al. (2016) evaluated 
different time points from the time points investigated in 
the present study. In addition, Kobayashi et al. (2016) used 
a shaking incubator before performing the ELISA evalua-
tion, whereas our group incubated the PRF-based matrices 
without further manipulation, which can also be a reason 
for the discrepancies revealed in the results. It is evident 
that detection of the specific growth factors is dependent 
on the specific methods employed. Thus, further studies in 
this field are necessary to develop and evaluate PRF-based 
matrices generated according to LSCC.
The present experimental design regarding the prepa-
ration and cultivation of PRF-based matrices may offer 
advantages because the PRF clots were not compressed or 
manipulated but nevertheless yielded the large amount of 
growth factors in the PRF clot. Furthermore, the clots were 
incubated in a cell culture environment to provide adequate 
gas exchange and optimal conditions for cells. The pri-
mary limitation of this study is the in vitro system issue. A 
comparison with clinical results is difficult because of the 
discrepancy of comparing the physiological environment 
in  vivo. Thus, the cellular crosstalk and enzymatic deg-
radation of the fibrin network would be different in  vivo. 
Further in vivo studies are required to determine the influ-
ence of the growth factors on the regeneration pattern of 
PRF-based matrices, particularly those matrices that are 
prepared according to the LSCC. This is necessary to iden-
tify out whether the observed inflammatory cell and growth 
factor enhancement will contribute to an improved regen-
eration potential in vivo. Moreover, the optimal release of 
growth factors required in wound healing and regeneration 
processes remains unclear, as is whether enhancing the 
amount released will indeed lead to improved performance. 
Thus, controlled clinical studies are essential to evaluate 
the regeneration potential of A-PRF and A-PRF+ and to 
establish the extent to which homogeneously distributed 
platelets and an enhanced growth factor release in addition 
to the porous structure will contribute to improved wound 
healing.
Less is known regarding the interaction of the PRF-
based matrices with biomaterials with a view to improving 
biomaterial-based regeneration. In addition, little atten-
tion has been focused on the composition of PRF-based 
matrices obtained from patients undergoing pharmaco-
logic treatments and whether the growth factor release will 
be influenced by medication. In addition, the regeneration 
potential of the PRF-based matrices may also be related to 
the age of the donor. Therefore, it may be that as the age 
of donors increases, less growth factor is released and vice 
versa. If this scenario is true, PRF-based matrices with 
enhanced growth factor release may be beneficial in these 
specific cases. In this respect, the determination of mono-
nuclear cell growth in PRF and penetration into the PRF-
based matrices as a simulation of the regeneration process 
in  vitro would be of interest in understanding the role of 
PRF-based matrices in biomaterials and tissue engineering. 
Hence, further studies of the PRF-based matrices as a com-
plex system that influences cell growth and differentiation 
and provides a growth factor reservoir remain necessary.
Additionally, the current PRF-based matrices were pre-
pared according to specific protocols with a defined amount 
of blood. However, it would be interesting to determine 
how increasing or decreasing the blood volume influences 
the composition of the prepared PRF-based matrices, their 
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regenerative potential and their growth factor release. These 
questions are current investigation topics of our research 
group as we seek to enhance wound healing and tissue 
regeneration to decrease patient morbidity. Hence, the out-
comes of this study could provide new clinical approaches 
in tissue and bone regeneration in terms of a combination 
of biomaterials with PRF-based matrices. Nevertheless, 
further studies, particularly clinical studies, are required to 
develop optimized, standardized and tailored preparation 
protocols for various clinical applications and to demon-
strate their advantages now and in the future.
Conclusion
The present study demonstrates the influence of RCF 
reduction on the growth factor release and platelet distribu-
tion in solid PRF-based matrices. A-PRF+, prepared with 
a reduced RCF, displayed significantly higher VEGF con-
centration over the study period of 10 days than A-PRF and 
PRF, which exhibited no statistically significant difference. 
EGF and TGF-β1 were comparable in A-PRF and A-PRF+, 
which were significantly higher than PRF. Additionally, the 
platelet distribution pattern appeared to be equivalent in 
all regions concerning A-PRF and A-PRF+, whereas PRF 
showed the largest accumulation of platelets in the lower 
portion of the clot. Long-term, sustained and slow release 
of growth factors from all of the PRF groups may support 
cell migration and cell proliferation as well as offer advan-
tages in the wound healing process. However, the signifi-
cantly enhanced release in A-PRF and A-PRF+ may render 
these matrices superior to PRF in specific clinical indica-
tions. These promising findings offer an excellent handling 
efficiency and new approaches to the clinical application of 
wound healing as well as soft and bone tissue regeneration. 
Nevertheless, further clinical studies must demonstrate the 
extent to which the application of LSCC to generate A-PRF 
and A-PRF+ will benefit clinical outcomes.
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